As a new dual receptor (PSMA and FAP) targeting PET radiotracer, 68Ga-PSFA is promising as an excellent imaging agent applicable to PSMA/FAP positive diseases. In this research, we investigate the safety, biodistribution and potential usefulness of 68Ga-PSFA positron emission tomography (PET) for the diagnosis of lesions in PSMA/FAP positive diseases.
Study Type
INTERVENTIONAL
Allocation
NA
Purpose
DIAGNOSTIC
Masking
NONE
Enrollment
30
Each subject receives a single intravenous injection of 68Ga-PSFA.
The First Affiliated Hospital of Chongqing Medical University
Chongqing, Chongqing Municipality, China
RECRUITINGDiagnostic efficacy
The sensitivity, specificity, and accuracy of 68Ga-PSFA PET
Time frame: 15 days
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.